Climb Bio, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated State ments of Cash Flows
(In thousands)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(73,897) | $(35,119) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 5,557 | 12,806 |
| Right-of-use asset impairment | — | 180 |
| Non-cash operating lease expense | 220 | 405 |
| Accretion of discounts and amortization of premiums on investments, net | (757) | (2,331) |
| In-process research and development, related party | 51,659 | — |
| Foreign currency gain from remeasurement | (42) | (304) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 1,942 | 7,370 |
| Long-term assets | (200) | 115 |
| Accounts payable | (963) | (686) |
| Accounts payable and accrued liabilities, related party | (177) | — |
| Accrued expenses and other liabilities | 1,445 | (2,613) |
| Long-term liabilities | (22) | 22 |
| Operating lease liabilities | (327) | (444) |
| Net cash used in operating activities | $(15,562) | $(20,599) |
| Cash flows from investing activities: | ||
| Issuance of promissory loan in connection with asset acquisition | (5,000) | — |
| Cash paid in connection with asset acquisition, net of cash acquired | (4,645) | — |
| Purchase of marketable securities | (132,197) | (58,449) |
| Proceeds from maturities of marketable securities | 20,750 | 127,430 |
| Net cash (used in) provided by investing activities | $(121,092) | $68,981 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in private placement, net of issuance costs | 119,750 | — |
| Proceeds from exercise of stock options | 10,979 | 841 |
| Net cash provided by financing activities | $130,729 | $841 |
| Effect of exchange rate changes on cash | 42 | 304 |
| Net change in cash and cash equivalents | $(5,883) | $49,527 |
| Cash and cash equivalents at beginning of period | 93,112 | 43,585 |
| Cash and cash equivalents at end of period | $87,229 | $93,112 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for leases included in operating cash outflows | $350 | $507 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Issuance of common stock in exchange for in-process research and development | $41,867 | $— |
| Settlement of promissory loan in connection with asset acquisition | $5,036 | $— |
| Right-of-use assets obtained in exchange for lease liabilities | $510 | $313 |
CLIMB BIO, INC
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.